^
BIOMARKER:

MYC amplification

i
Other names: MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
Entrez ID:
MYC amplification
HER2 Positive Breast Cancer
trastuzumab + atezolizumab + pertuzumab
Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
MYC amplification
NSCLC
gefitinib
Sensitive: B - Late Trials
MYC amplification
Small Cell Lung Cancer
AZD1775
Sensitive: C2 – Inclusion Criteria
MYC amplification
Esophageal Cancer
ibrutinib
Sensitive: C2 – Inclusion Criteria
MYC amplification
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
MYC amplification
Ovarian Cancer
durvalumab
Resistant: C3 – Early Trials
MYC amplification
Triple Negative Breast Cancer
talazoparib
Resistant: C3 – Early Trials
MYC amplification
NSCLC
osimertinib
Resistant: C3 – Early Trials
MYC amplification
Ovarian Cancer
bevacizumab
Sensitive: C3 – Early Trials
MYC amplification
Small Cell Lung Cancer
talazoparib + GSK525762
Sensitive: D – Preclinical
MYC amplification
Triple Negative Breast Cancer
YPN-005
Sensitive: D – Preclinical
MYC amplification
HCC
YPN-005
Sensitive: D – Preclinical
MYC amplification
Estrogen Receptor Positive Breast Cancer
YPN-005
Sensitive: D – Preclinical
MYC amplification
Pancreatic Cancer
YPN-005
Sensitive: D – Preclinical
MYC amplification
Prostate Cancer
YPN-005
Sensitive: D – Preclinical
MYC amplification
Small Cell Lung Cancer
YPN-005
Sensitive: D – Preclinical
MYC amplification
Ovarian Cancer
YPN-005
Sensitive: D – Preclinical
MYC amplification
Small Cell Lung Cancer
LY2606368
Sensitive: D – Preclinical
MYC amplification
Medulloblastoma
PCM-075
Sensitive: D – Preclinical
MYC amplification
Small Cell Lung Cancer
APR-246
Sensitive: D – Preclinical
MYC amplification
Ovarian Cancer
KB-0742
Sensitive: D – Preclinical
MYC amplification
Colon Cancer
KB-0742
Resistant: D – Preclinical
MYC amplification
HCC
KB-0742
Resistant: D – Preclinical
MYC amplification
Gastric Cancer
KB-0742
Resistant: D – Preclinical
MYC amplification
Esophageal Cancer
KB-0742
Resistant: D – Preclinical
MYC amplification
Head and Neck Cancer
KB-0742
Resistant: D – Preclinical